LONDON, May 22, 2015 /PRNewswire/ --
Richmond Pharmacology is a university affiliated early phase clinical research unit with a worldwide reputation for excellence in clinical trials. It is respected for its frequent publications in peer reviewed medical journals. Its officers are engaged with UK and European stakeholders and regulators in discussions about rules for transparency and publication of clinical trial results.
Clinical research is conducted worldwide, therefore it is important to set transparency rules that are acceptable and enforceable across geographic regions.
Richmond Pharmacology strongly believes that the Health Research Authority (HRA) has acted unlawfully in respect of the implementation of its transparency policy; Richmond Pharmacology has been forced to bring a Judicial Review process, because the HRA persistently refused to consider its legal position whilst making this stance clear in public meetings.
Richmond Pharmacology welcomes the Court's recent decision to grant permission to bring this Judicial Review and looks forward to the Court's decision in July.
SOURCE Richmond Pharmacology Ltd